Regencell Bioscience Holdings Limited Announces Registered Direct Offering of Ordinary Shares

Regencell Bioscience Holdings Limited has announced a registered direct offering of ordinary shares, entering into a definitive agreement with investors for the purchase and sale of 985,222 ordinary shares at a price of $20.30 per share. The offering, which includes a $19 million investment from a new institutional investor and participation from Univest Securities, LLC, is expected to yield approximately $20.0 million in gross proceeds. The transaction is anticipated to close around May 20, 2026. Univest Securities is serving as the sole placement agent for this offering, which is being conducted under a shelf registration statement on Form F-3. The company, focused on developing Traditional Chinese Medicine for neurocognitive disorders, will file a prospectus supplement with the SEC detailing the offering.